Meet us at USCAP 2023 in New Orleans
We are thrilled to announce that we will be attending the upcoming USCAP annual conference taking place in New Orleans from March 11-16. Our team is excited to meet you and share all the exciting updates we have in store for you. Read on for more information about our activities at the conference.
Looking to overcome the IT and installation challenges of implementing a digital pathology workflow?
You're invited to try out and get a sneak peak of Oncotopix Cloud, a new AI-powered solution that enables easy accessibility to automated image analysis for pathology labs that do not have a full digital workflow and infrastructure. The cloud-based platform eliminates the need for software installation and allows easy analysis of images. It offers a graphical user interface accessible via the web, allowing users to upload images for analysis by pre-existing, fully automated, APPs in the cloud. The current menu includes PD-L1 and Ki-67, with plans to expand to other existing APPs like ER/PR/HER2 and more.
Simply bring your anonymized Ki67 or PD-L1 images to our booth, and we will upload them together to the platform. It will automatically analyze the slides and send you an email report with results. If you don't have slides available, we have test slides for you to use.
Discover our IVDR-cleared and fully automated next-generation Ki67 algorithm for IHC biomarker analysis
Visit our booth to learn about our new next-generation Ki67 algorithm that provides diagnostic decision support for pathologists. The algorithm has been cleared under the European In-Vitro Diagnostic Regulations (IVDR) and is designed to be fully automated, enabling pathologists to become more productive without manual steps.
Paul van Diest, Head of Pathology at UMC Utrecht, had this to say about it:
"The Visiopharm algorithm is helping us achieve standardization in the scoring of Ki67 for breast cancer patients. We look forward to having the algorithm fully automated and integrated into our workflow, saving us time and effort while also improving the accuracy and consistency of our results."
If you cannot wait until USCAP starts or you are not attending, you can read about it here.
Presentations
Monday, March 13 – Einstein, Tolkien, and AI: An explorer's quest to push the limits of digital pathology
5:30pm–7pm
Free drinks and finger food for all attendees.
Our guest speaker, Dr John Groth, will present, Einstein, Tolkien, and AI: An explorer's quest to push the limits of digital pathology.
This talk promises to be an unforgettable experience that will provide attendees with a unique perspective on the future of digital pathology and the impact of AI on healthcare.
About John Groth
John Groth, M.D., is a pathologist and anatomic pathology informatics director at NorthShore University HealthSystem leading the transition to a digital workflow with AI incorporation for primary anatomic pathology clinical work. He has completed studies and fellowships in general surgical pathology, cytopathology, and clinical informatics. Dr Groth is also a member of several medical societies and has been recognized for his academic, educational, and scholarly efforts.
Wednesday, March 15 (event hosted by our partner, Agilent)
12–1pm – How an open, scalable digital pathology solution can improve diagnostic quality and efficiency in pathology practice
Lunch will be served during the seminar.
Head to Exhibitor Seminar Room #3 for Agilent's seminar on, How an open, scalable digital pathology solution can improve diagnostic quality and efficiency in pathology practice. Join their speakers, including our Senior Vice President in Global Clinical Sales, Martin Kristensson, and discover how digital pathology can help streamline laboratory processes and enhance patient outcomes. This seminar will showcase real-world examples of new agnostic tools used in pathology labs to improve diagnostic quality and efficiency.
Speakers: Giovanni Lujan (Associate Professor of Pathology and Director of Digital and Computational Pathology at Ohio State University), Martin Kristensson (Senior Vice President, Global Clinical Sales, Visiopharm), and Alan Byrne (Agilent Technologies Inc Principal Global Product Manager, Digital Pathology) will moderate.
Posters
Are you looking to stay up-to-date with the latest trends in pathology research? Then be sure to visit the Poster Wall.
Title: Artificial Intelligence Assisted Assessment of HER2 IHC Using Semi- and Fully-Automated Workflows: Rapid Validation and Implementation as a Quality Assurance and Risk Mitigation Check Point.
Authors: Ursula Green, Massachusetts General Hospital; Jenifer Caldara, Visiopharm; Danielle Pirain, Visiopharm; Regan Baird, Visiopharm; Jochen K. Lennerz, Massachusetts General Hospital, Harvard Medical School.
Abstract: This study yielded results which validated the Visiopharm HER2 APP for use in routine workflows and demonstrated that it can be validated and implemented within two days for QC and risk mitigation.
When and where: Tuesday, March 14, 9:30am – 12pm, Exhibit Hall B, Board #26
Title: A Comprehensive Guided Workflow for Highplex Imaging: Cell and Tissue Segmentation and Multiplex Cellular Phenotyping for Tumor Microenvironment Analysis
Authors: James Mansfield, Jeppe Thagaard, Brenna O´Neil, Regan Baird, Fabian Schneider from Visiopharm.
Abstract: This study demonstrates that a simple, guided workflow can be used to analyze highplex images of different tissue types with no programming knowledge.
When and where: Tuesday, March 14, 9:30am – 12pm, Exhibit Hall B, Board #178
Title: Deep Learning-Based, Fully Automated Analysis of Whole Slide Images Can Detect Invasive Breast Carcinoma and Count Ki-67 Easily and Precisely
Authors: Akira I. Hida, Dr., MD, PhD, Matsuyama Shimin Hospital; Jeppe Thagaard, N/A, Visiopharm A/S; Takahiro Watanabe, MD,PhD, Hyogo College of Medicine; Thomas Ramsing, MSc, Visiopharm A/S; Agnete Overgaard, PhD, Visiopharm A/S; Yumi Oshiro, MD, PhD, Matsuyama Red Cross Hospital; Takuya Moriya, MD, Kawasaki Medical School
Abstract: The study compared results of Ki-67 quantification for breast cancer cases of two pathologists with the output of a fully automatic DL-based Ki-67 APP.
When and where: Tuesday, March 14, 9:30am – 12pm, Exhibit Hall B, Board #15
Title: T Cell Activation but Not Hemosiderosis is Important in Onset and Maintenance of Injury in Nonalcoholic Steatohepatitis
Authors: H. Yousaf et al. from the University of Minnesota
Abstract: Immunologic and hemosiderotic factors have been rarely studied in NAFLD. This study aims to investigate the role of these factors.
When and where: Tuesday, March 14, 9:30am – 12pm, Exhibit Hall B, Board #88
Title: Validating Automated Digital Image Analysis Algorithm to Identify HER2-low Breast Carcinomas
Authors: A. K. Chow et al. from the Ohio State University
Abstract: The study examined the capabilities of automated DIA on discriminating HER2-low cases from HER2 0 cases and showed a substantial agreement with pathologist scoring.
When and where: Tuesday, March 14, 9:30am – 12pm, Exhibit Hall B, Board #25
Title: Digital imaging analysis of HER2 Immunohistochemistry in Cytology slides
Authors: S. Akbar et al. from the Ohio State University
Abstract: Visiopharm’s HER2 APP is validated on surgical specimens. This study aims to validate the APP in cytology specimens from metastatic breast cancer samples.
When and where: Tuesday, March 14, 9:30am – 12pm, Exhibit Hall B, Board #54
Do you have questions about digital pathology? Visit our friendly team at booth #103 and get the answers you need. Our experts are available to provide you with the latest insights on digital pathology techniques and applications. Keep an eye out for the friendly faces – they're waiting to welcome you to our booth.
Danielle Pirain, New Business Account Executive
Brit Boehmer, New Business Account Executive
Jeni Caldara, Technical Sales Manager
Martin Kristensson, Senior Vice President, Global Clinical Sales
Jeppe Thagaard, Head of AI
If you have a burning question you can't wait to ask at USCAP, don't hesitate to get in touch with our team here.